<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00528242</url>
  </required_header>
  <id_info>
    <org_study_id>SLx-2101-07-04</org_study_id>
    <nct_id>NCT00528242</nct_id>
  </id_info>
  <brief_title>Safety, Tolerability, and Pharmacodynamic Profile of Oral 2101 in Secondary Raynaud's Disease</brief_title>
  <official_title>A Randomized, Double Blind, Placebo-controlled, Cross-over Pilot Study to Examine the Safety, Tolerability and Pharmacodynamic Profile of Repeat Oral Doses of SLx-2101 Once Daily for up to 14 Days in Subjects With Secondary Raynaud's Disease.</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Kadmon Corporation, LLC</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Kadmon Corporation, LLC</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      To investigate the severity of secondary Raynaud's disease-related attacks during the 14 days
      2101 dosing period.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      1. Number and cumulative duration of Raynaud's attacks.

        2. Adverse events and changes in vital signs.

        3. SLx-2101 pharmacokinetic parameters derived after dosing on Day 1 and Day maximum plasma
           concentration (Cmax), area under the plasma concentration-time curve (AUC0-4), time to
           Cmax (tmax), and accumulation ratio
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>June 2007</start_date>
  <completion_date type="Actual">March 2008</completion_date>
  <primary_completion_date type="Actual">March 2008</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Crossover Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Double (Participant, Investigator)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Raynaud's condition scores after 14 days of SLx-2101</measure>
    <time_frame>14 days</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Safety and tolerability</measure>
    <time_frame>14 days</time_frame>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">17</enrollment>
  <condition>Raynaud's Disease</condition>
  <arm_group>
    <arm_group_label>1</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>SLx-2101</description>
  </arm_group>
  <arm_group>
    <arm_group_label>2</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Matching Placebo Dose</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>SLx-2101</intervention_name>
    <arm_group_label>1</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Placebo</intervention_name>
    <arm_group_label>2</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  male and female ages 18 and 65 y.o.

          -  BMI Body weight within a body mass index range of 17 - 30 kg/m2 (inclusive).

        Exclusion Criteria:

          -  Hypersensitivity to the active substance of SLx-2101or to any of the excipients.

          -  Past or present disease that is judged by the Investigator to have the potential to
             interfere with the study procedures, compromise safety, or affect the pharmacokinetic
             and pharmacodynamic evaluations
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>65 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>M Baumaker, MD</last_name>
    <role>Study Director</role>
    <affiliation>University des Saarlandes</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>University des Saarlandes</name>
      <address>
        <city>Homburg</city>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Germany</country>
  </location_countries>
  <verification_date>January 2015</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>September 11, 2007</study_first_submitted>
  <study_first_submitted_qc>September 11, 2007</study_first_submitted_qc>
  <study_first_posted type="Estimate">September 12, 2007</study_first_posted>
  <disposition_first_submitted>December 9, 2014</disposition_first_submitted>
  <disposition_first_submitted_qc>December 9, 2014</disposition_first_submitted_qc>
  <disposition_first_posted type="Estimate">December 31, 2014</disposition_first_posted>
  <last_update_submitted>January 26, 2015</last_update_submitted>
  <last_update_submitted_qc>January 26, 2015</last_update_submitted_qc>
  <last_update_posted type="Estimate">February 2, 2015</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Raynaud Disease</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted, but a results disposition has been submitted           -->
</clinical_study>

